- Home
- THAR vs MBIO Comparison
THAR vs MBIO Comparison
Compare THAR & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- MBIO
- Stock Information
- Founded
- THAR 2017
- MBIO 2015
- Country
- THAR United States
- MBIO United States
- Employees
- THAR 3
- MBIO N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- MBIO Health Care
- Exchange
- THAR Nasdaq
- MBIO Nasdaq
- Market Cap
- THAR 16.8M
- MBIO 4.7M
- IPO Year
- THAR 2022
- MBIO N/A
- Fundamental
- Price
- THAR $3.14
- MBIO $1.58
- Analyst Decision
- THAR Strong Buy
- MBIO
- Analyst Count
- THAR 1
- MBIO 0
- Target Price
- THAR $17.00
- MBIO N/A
- AVG Volume (30 Days)
- THAR 29.4M
- MBIO 119.0K
- Earning Date
- THAR 11-06-2025
- MBIO 11-07-2025
- Dividend Yield
- THAR N/A
- MBIO N/A
- EPS Growth
- THAR N/A
- MBIO N/A
- EPS
- THAR N/A
- MBIO N/A
- Revenue
- THAR N/A
- MBIO N/A
- Revenue This Year
- THAR N/A
- MBIO N/A
- Revenue Next Year
- THAR N/A
- MBIO N/A
- P/E Ratio
- THAR N/A
- MBIO N/A
- Revenue Growth
- THAR N/A
- MBIO N/A
- 52 Week Low
- THAR $0.95
- MBIO $0.89
- 52 Week High
- THAR $9.08
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- THAR 48.05
- MBIO 50.09
- Support Level
- THAR $2.75
- MBIO $1.31
- Resistance Level
- THAR $3.46
- MBIO $1.59
- Average True Range (ATR)
- THAR 1.23
- MBIO 0.09
- MACD
- THAR -0.32
- MBIO 0.01
- Stochastic Oscillator
- THAR 6.16
- MBIO 72.97
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.